Pfizer's (PFE -0.3%) Dacomitinib drug has failed in two Phase III trials of patients with refractory advanced non-small cell lung cancer.
In the ARCHER 1009 trial, which included patients previously treated with chemotherapy, Dacomitinib did not significantly improve progression-free survival (PFS) when compared with the Erlotinib (Tarceva) drug.
In the second study, Dacomitinib was unable to lengthen survival vs a placebo.
A third Phase III trial is assessing Dacomitinib in a different patient population, with the results expected in 2015. (PR)